# Original Article BMSCs-induced CD45RB<sup>+</sup> dendritic cells suppress T cell activity

Fei Hua<sup>\*</sup>, Ziying Yang<sup>\*</sup>, Xiaomei Teng, Yueqiu Chen, Haoyue Huang, Daguang Cui, Yunfeng Zhao, Zhenya Shen

Department of Cardiovascular Surgery, Institute of Cardiovascular Science, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, China. \*Equal contributors and co-first authors.

Received September 4, 2016; Accepted November 29, 2016; Epub February 15, 2017; Published February 28, 2017

**Abstract:** Mesenchymal stem cells (MSCs) exhibit strong immunoregulatory capabilities, however the mechanism by which MSCs regulate T cell function via modulating dendritic cell (DC) activity is poorly understood. Rat MSCs and DCs were isolated from bone marrow, and CD4<sup>+</sup> T cells were isolated from the spleen. DCs were co-cultured with Lipopolysaccharide and MSCs, and after 5 days, DC cell surface markers were assessed by flow cytometry. CD45RB<sup>+</sup> DCs were then isolated and expression of costimulatory molecules, Foxp3, and antigen uptake capability was assessed. We also incubated CD4<sup>+</sup> T cells in the presence or absence of conA, CD45RB<sup>+</sup> DCs, immature DCs (imDCs) and mature DCs (mDCs) and then measured T cell proliferation, T-bet, GATA-3, RORyt, and Foxp3 mRNA content by qPCR, and supernatant cytokine content by cytometric bead array. MSC-DC co-culture induced CD45RB and ILT4 expression, and reduced CD86 and MHC-II expression typical of imDCs. Proliferation of T cells incubated with imDCs and CD45RB<sup>+</sup> DCs was significantly higher levels of GATA-3 and Foxp3 mRNA and lower levels of T-bet and RORy mRNA, and released higher levels of IL-4 and lower levels of IL-2, IFN-Y, IL-17A, IL-6 and TNF- $\alpha$  than those co-cultured with mDCs. Rat bone marrow derived MSC induce CD45RB<sup>+</sup> DC differentiation, therefore promoting differentiation of T cells to Th2 and CD4<sup>+</sup>Foxp3<sup>+</sup> T cells.

Keywords: Mesenchymal stem cells, dendritic cells, CD45RB, CD4<sup>+</sup> T cells, immunosuppression

#### Introduction

The capacity of mesenchymal stem cells (MS-Cs) to differentiate into mesenchymal lineages and exert immune-regulatory effect suggests that MSC transplantation may confer clinical benefits to a range of conditions [1-6]. Specifically, MSCs can regulate innate and acquired immune responses by directly modifying T and B cell responses, or indirectly affecting differentiation of T and/or B cells, or myeloid-derived cells (e.g. dendritic cells, DCs) and macrophages [7, 8]. These extraordinary capabilities suggest that transplantation of MSCs may represent a clinically useful treatment for graft versus host disease (GVHD) [7]. Although the mechanisms by which MSC modulate the behaviors of T cells, B cells and macrophages have been well studied, little is known about the mechanism by which MSCs regulate DC activity.

As the most important antigen presenting cells in the body, DCs process and present antigens mainly to naive and memory T cells. However, in order to initiate an immune response, DCs must mature; immature DCs are not only incapable of adequately activating T cells but can also induce tolerance [9]. MSCs can regulate the recruitment, maturation, and function of DCs, and have been reported to significantly reduce monocyte differentiation into DCs, downregulateCD40, CD80, CD86, and MHC II [10-12]. MSCs also inhibit DC secretion of IL-12, the deficiency of which may induce T cell anergy and tolerance [13]. Recently, Sadeghiet al. discovered that bone marrow derived MSCs (BM-MSCs) can inhibit the maturation of splenic DCs, and thus drive responding T cells toward Th2 cytokine responses [14]. However, the precise mechanism by which MSCs regulate T cells though DCs modification is not yet clear.

DCs represent a heterogeneous population, expressing a range of different types and levels of surface markers [15]. For example, DCs expressing high levels of CD11c and no CD45RB are termed CD11c<sup>high</sup>CD45RB<sup>-</sup> DCs, and are found to mainly secrete IL-12. In contrast, CD-11clowCD45RB+ DCs are found to mainly secrete IL-10 [16-18]. CD11c<sup>low</sup>CD45RB<sup>+</sup> have been reported to suppress immune responses by inducing tolerance and differentiation of regulatory T cells (Tregs) in vivo [19]. Based on these observations, we postulated that co-incubation of DCs with MSCs may induce maturation of CD11c<sup>low</sup>CD45RB<sup>+</sup> DCs, which can subsequently regulate the behavior of T cells and exert an immunosuppressive effect. In this study, we demonstrated that co-incubation of DCs with MSCs induced maturation of DCs expressing higher levels of CD45RB and ILT4, and lower levels of CD86 and MHC-II. These CD45RB<sup>+</sup> DCs exhibit surface marker expression patterns and antigen uptake capability more similar to immature DCs. Isolated CD45RB<sup>+</sup> DCs inhibited the proliferation of CD4+ T cells, induced the differentiation of CD4<sup>+</sup> T cells to Th2 and Tregs.

# Methods and materials

#### Rats

Wistar rats (weight: 200-250 g) were provided by the Laboratory Animal Center of Soochow University (Suzhou, China). Animals were maintained under specific pathogen free and standard conditions. All experimental procedures involving animals were approved by the animal ethical committee of Soochow University.

#### Isolation and culture of cells

MSCs were isolated from rat bone marrow as previously described [20, 21]. Briefly, bone marrow cells were isolated from femurs and tibias of Wistar rats. Isolated cells were cultured in flasks in DMEM (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA) in a  $CO_2$  incubator at 37°C. After 3 days, non-adherent cells were removed. Adherent cells were grown to 85% confluency, then trypsinized and passaged. At passage 3, osteogenic and adipogenic differentiation was assessed by measurement of MSC surface expression of CD90, hematopoietic markers CD45 and monocyte cell marker CD11b/c by flow cytometry, as previously described [22]. Immature DCs were also derived from the femur and tibia bone marrow of Wistar rats. Briefly, bone marrow was collected from femurs and passed through a 100-µm pore size mesh to remove fibrous tissue. Red blood cells were lysed, and the remaining cells were cultured at  $1\times10^6$  cells/ml in RPMI 1640 medium (Hyclone, USA) supplemented with cytokines (10 ng/ml each of mouse GM-CSF and IL-4; R&D, USA). After 5 days, cells were harvested and the immature DCs (imDCs) phenotypewas analyzed by flow cytometry (Becton Dickson, USA) [23].

Naive CD4<sup>+</sup> T cells were isolated from the rat spleen as previously described [24]. Briefly, spleen cells were labeled with CD11b, TER-119, Gr-1, I-A/I-E, CD8 $\alpha$ , B220, and Gr-1 directed mAbs (BD Pharmingen), and opsonized cells were removed by Dynabeads (Dynal Biotech). Purity of the remaining CD4<sup>+</sup> cells was consistently 90-95%.

## Co-incubation of MSCs or T cells with DCs

To investigate the effect of MSCs on DC maturation, 10<sup>6</sup> freshly harvested imDCs were plated in 6-well plates with the same number of MSCs at a 1:1 ratio. MSCs were not irradiated before co-culture. The mixed cells were incubated in 2 ml of RPMI 1640 medium supplemented with 10% FBS, stimulated with lipopolysaccharide (LPS) (200 ng/mL final concentration, Sigma, USA) and in presence or absence of MSC for 5 days. Expression of PDL1, ILT4, CD1d, CD14, CD45RA, CD45RB, CD40, CD80, CD86 and MHC-II was then assessed by flow cytometry, and imDCs, MSCs+LPS-induced DCs (CD45RB<sup>+</sup> DCs) and LPS-induced DCs (mature DC) were isolated. Immature DC and mature DCs were separated according to CD86/ CD80 expression level, and CD45RB<sup>+</sup> DCs were separated according to CD45RB expression, via fluorescence-activated cell sorting.

To explore the effects of imDCs, mDCs and CD45RB<sup>+</sup> DCs on CD4<sup>+</sup> T cells, DCs were coincubated with CD4<sup>+</sup> T cells at a 1:10 ratio in RPMI 1640 medium supplemented with 10% FBS and conA (10 ng/ml final concentration, Sigma, USA) in 6-well plates for 3 days. CD4<sup>+</sup> T cells were then harvested by fluorescence-activated cell sorting, and the percentage of CD4<sup>+</sup> Foxp3<sup>+</sup> Treg was determined by flow cytometry. The supernatant was collected for cytometric bead array (CBA).

Primers	Sequences (5'-3')
Foxp3-F	ACACCCAGGAAAGACAG
Foxp3-R	GGCAGTFCTTFAFAAAC
T-bet-F	GTTCCCATTCCTGTCCTTC
T-bet-R	CCTTGTTGTTGGTGAGCTT
GATA3-F	TTTACCCTCCGGCTTCATCCTCCT
GATA3-R	TGCACCTGATACTTGAGGCACTCT
RORyt-F	GGAGCTCTGCCAGAATGAGC
RORyt-R	CAAGGCTCGAAACAGCTCCAC
β-actin-F	GGTGTGATGGTGGGAATGGG
β-actin-R	ACGGTTGGCCTTAGGGTTCAG

Table 1. Primers used in qPCR

## DC antigen uptake assay

A total of 1.0×10<sup>6</sup> imDCs, CD45RB<sup>+</sup> DCs or mDCs were incubated with latex beads/FITC-OVA (DC/Bead at ratio of 1:20000) at 37°C. After 1, 3, 6 or 24 h, cells were harvested and antigen uptake was assessed. After quenching the unincorporated FITC signal with 0.4% trypan blue, uptake was quantified as mean cellassociated fluorescence intensity measured by flow cytometry.

# Real-time qRT-PCR

The FOXP3 mRNA content of imDCs, CD45RB<sup>+</sup> DCs or mDCs and the T-bet, GATA-3, RORyt, Foxp3 mRNA content of T cells co-incubated with or without these DCs were determined by qPCR using Revert Aid First Strand cDNA Synthesis Kit (Thermo, USA) and SYBR Green Realtime PCR Master Mix (Life, USA) following the manufacturer's instructions using the primers listed in **Table 1**.

# Western blot

FOXP3 expression in imDCs, CD45RB<sup>+</sup> DCs or mDCs was determined by western blot (ebioscience), as previously described [25, 26].

# Proliferation test

The effect of DCs on T cell proliferation was determined by CCK-8 assay. Briefly, imDCs, CD45RB<sup>+</sup> DCs and mDCs were inactivated by co-incubation with mitomycin (25 ug/mL, Sigma, USA) for 45 min at 37°C in 5% CO<sub>2</sub>. Then mitomycin was removed and cells were washed twice with PBS. Then DCs were plated in 96-well plates at density of  $1 \times 10^{5}$ /well and co-incubated with or without T cells ( $1 \times 10^{5}$ /well) and conA (10 ng/ml) at 37°C in 5% CO<sub>2</sub> for 5 days. CCK-8 (10 µl/well) was added and the plates were

incubated for additional 4 h. The OD values at 450 nm were determined by a microplate reader (CliniBio128C, Austria).

# Detection of cytokines

The cytokine content of co-culture supernatant was assessed by CBA using the human Th1/Th2/Th17 kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer instructions. We measured IL-2, IL-10, IL-4, IL-6, IFN- $\gamma$ , TNF- $\alpha$ , and IL-17A.

# Statistical analysis

Data was presented as Mean  $\pm$  SD, and analyzed using ANOVA post hoc LSD test with SPSS 18.0 and Graphpad Prism 5. *P*<0.05 was considered statistically significant.

# Results

# Characterization of rat BM-MSCs

Isolated bone BM-MSCs were initially observed to be round (**Figure 1A** and **1B**). After 3 passages, cells attached well and became striplike in appearance (**Figure 1C** and **1D**). Expression of CD90 and lack of CD45 and CD11b/ cexpressed in these cells indicated that they were MSCs (**Figure 1E**). Successful adipocyte or bone differentiation of these cells, induced by incubation with the corresponding mediums, was validated by Oil Red O and Alizarin Red S staining (**Figure 1F**), confirming that these cells were capable of adipocyte and bone differentiation.

Co-incubation with BM-MSCs induces DCs expression of CD45RB and ILT4, and reduces DC expression of CD86 and MHC-II

Cells (precursor cells of imDCs) isolated from bone marrow were incubated with GM-CSF and IL-4 for 7 days, and successful differentiation to imDCs was confirmed by flow cytometry (Figure 2A-C). These imDCs were then incubated with LPS in the presence or absence of BM-MSCs. Incubation with LPS alone induced imDC maturation to mDCs. However, when im-DCs were co-incubated with BM-MSCs and LPS, cell surface markers of these DCs differed from mDCs. As shown in Figure 2D, co-incubation of imDCs with MSCs significantly increased the fraction of DCs expressing CD45RB and ILT4, and reduced the fraction of DCs expressing CD86 and MHC-II (Figure 2D). Expression of PLD-1, CD45RA, CD1D and CD14 did not differ significantly between imDCs and mDCs.



**Figure 1.** Isolation and characterization of rat BM-MSCs. A and B. Morphology of MSCs at passage 0. C and D. Morphology of MSCs at passage 3. E. Cell surface makers of MSCs, assessed by flow cytometry at passage 3. F. Differentiated MSCs strained by Oil Red 0 (left) or Alizarin Red S (right). Adipocyte differentiation was induced and cells were strained by Oil Red 0. Bone differentiation of MSCs was induced and cells were strained by Alizarin Red S (200×).

Modulating dendritic cell suppress T cell activity





**Figure 3.** Surface markers and foxp3 expression in CD45RB<sup>+</sup> DCs. (A) CD80, CD86 and MHC-II expression in DCs was determined by flow cytometry. \*P<0.01 compared with mDC group, NS, no significant difference (B) Antigen uptake of DCs. imDCs, CD45RB<sup>+</sup> DCs or mDCs were incubated with latex beads/FITC-OVA. Uptake was quantified by measuring cell-associated fluorescence intensity by flow cytometry. \*P<0.05 compared with mDC group. (C) Foxp3 mRNA expression in different DCs was determined by q-PCR. \*P<0.05 compared with mDC group. (D) Foxp3 protein expression in different DCs was measured by western blot. \*P<0.05 compared with mDC group.

# $\text{CD45RB}^{\scriptscriptstyle +}$ DCs shows similar characteristics to imDCs

The CD45RB<sup>+</sup> DCs induced by co-incubation with BM-MSCs and LPS were isolated using flow cytometry. Purified CD45RB<sup>+</sup> DCs exhibit similar characteristics to imDCs, including surface marker expression pattern (**Figure 3A**), antigen uptake ability (**Figure 3B**), Foxp3 mRNA content (**Figure 3C**) and Foxp3 protein content (Figure 3D). These features differ significantly from those of mDCs, suggesting that BM-MSCs may inhibit the LPS-induced differentiation of imDCs to regulatory DCs.

CD45RB<sup>+</sup> DCs and imDCs inhibit the proliferation of CD4<sup>+</sup> T cells

Cell morphology indicted that proliferation of T cells cultured with imDCs+conA and CD45RB<sup>+</sup>



**Figure 4.** Effect of different DCs on proliferation of CD4<sup>+</sup> T cells. (A-E) T cell morphology. T cells were incubated alone (A) orintheor presence (B) of conA. Arrows indicate proliferating T cell colonies. T cells were co-incubated with imDC+conA (C), CD45RB<sup>+</sup>DC+conA (D) and mDC+conA (E). T cell morphology was captured by light microscope. (F) T cell proliferation was determined by CCK-8 assay. \*P<0.05 compared with conA group. #P<0.05 compared with imDC+conA and CD45RB<sup>+</sup>DC+conA groups.

DCs+conA was significantly lower than in cells incubated with conA (**Figure 4A-E**). CCK-8 assay confirmed that proliferation rate was significantly slower in T cells incubated with im-DCs and CD45RB<sup>+</sup> DCs than those incubated with conA alone, but significantly faster in T cells incubated with mDCs+conA than those incubated with conA alone, which indicated that mDCs promoted the proliferation of T cells (**Figure 4F**).

#### imDCs and CD45RB<sup>+</sup> DCs promote differentiation of T cell to Th2 and CD4<sup>+</sup>Foxp3<sup>+</sup> T cells

After co-incubation with different DCs for 3 days, T cells were isolated, and T-bet, GATA-3,

RORy, and Foxp3 mRNA content was measured by qPCR, indicating differentiation of T cells to Th1, Th2, Th17 or Treg, respectively. Compared with cells incubated with conA or mDCs+conA. T cells co-cultured with imDCs+ conA and CD45RB<sup>+</sup> DCs+conA expressed significantly higher levels of GATA-3 and Foxp3 mRNA and lower levels of T-bet mRNA (Figure 5A). T cells co-cultured with mDCs+conA expressed significantly higher levels of T-bet and RORy mRNA than those cocultured with imDCs+conA or CD-45RB+DCs+conA (Figure 5A). Tbet, GATA-3, RORy, and Foxp3 mRNA content did not differ significantly between T cells co-cultured with imDCs+conA and CD-45RB+DCs+conA.

Moreover, T cells co-cultured with imDCs+conA and CD45RB<sup>+</sup> DCs+ conA release higher levels of IL-4 and lower levels of IL-2, IFN- $\gamma$ , IL-17A, IL-6 and TNF- $\alpha$  (Figure 5B). Interestingly, IL-10 released from CD45RB<sup>+</sup> DCs+conA group was much high than from other group, IL-10 was the only cyto-kine expressed differently from imDCs+conA and CD45RB<sup>+</sup> DCs+ conA group.

troups. Lastly, the proportion of CD4<sup>+</sup> Foxp3<sup>+</sup> T cells in imDCs+conA and CD45RB<sup>+</sup> DCs+conA group was higher than that in mDC+conA group (Figure 5C).

#### Discussion

We postulated that co-incubation of DCs with MSCs may induce maturation of CD11c<sup>low</sup>CD-45RB<sup>+</sup> DCs, exert an immunosuppressive effect on T cells. To investigate this hypothesis we isolated rat BM-MSCs and prepared imDCs, and investigated the effect of MSCs on DC differentiation *in vitro*. Co-incubation with MSCs and LPS induced DC expression of CD45RB and ILT4, and down-regulated expression of CD86 and MHC-II. Isolation and characterization of





CD45RB<sup>+</sup> DCs indicated that MSCs-DC coincubation inhibited DC maturation. CD45RB<sup>+</sup> DCs exhibited similar surface biomarker pattern, antigen uptake ability and Foxp3 expression to imDCs.

Proliferation of T cells incubated with imDCs and CD45RB<sup>+</sup> DCs was significantly slower than that of T cells incubated with mDCs. T cells cocultured with imDCs and CD45RB<sup>+</sup> DCs expressed significantly higher levels of GATA-3 and Foxp3 and lower levels of T-bet and RORγ than T cells co-cultured with mDCs. Co-incubation of T cells with CD45RB<sup>+</sup> DCs enhanced release of IL-4 and reduced release of IL-2, IFN- $\gamma$ , IL-17A, IL-6 and TNF- $\alpha$ , indicating promotion of T cells.

MSCs were previously reported to exhibit immunosuppressive effects by directly modulating T cell survival, proliferation and differentiation [7], and MSCs have also been reported to modulate the behavior of T cells indirectly, specially via DCs. MSCs can inhibit differentiation of monocytes into imDCs [13] by blocking monocyte cell cycle at the G0 phase [27]. MSCs also inhibited maturation of imDCs and furthermore downregulated expression of CD86/CD80 and MHC-II [10], and reduce secretion of TNF- $\alpha$  and IL-12p70 from immature DCs, while increasing production of IL-10 [28, 29]. Our results confirmed that BM-MSCs downregulate DC expression of CD86 and MHC-II.

We found that imDCs-MSC co-incubation promoted up-regulated DC expression of CD45RB<sup>+</sup>. Purified CD45RB<sup>+</sup> DCs exhibited similar surface marker expression, antigen uptake and Foxp3 expression to imDCs. These observations are consistent with previous reports that BM-MSCs inhibited maturation of imDCs into mDCs.

We also discovered that imDCs and CD45RB<sup>+</sup> DCs expressed higher levels of Foxp3 than mDCs. Foxp3 is a typical Treg biomarker and immunosuppressive factor, but Foxp3 expression in DCs was rarely evaluated. Our results suggest that in DCs Foxp3 may act as a specific biomarker distinguishing imDCs and CD45RB<sup>+</sup> DCs from mDCs.

Additionally, the expression of Foxp3 may indicate the mechanism by which this imDCs and CD45RB<sup>+</sup> DCs exert immunosuppressive functions. It is well understood that immature DCs cannot activate T cells, and, in fact, induce immune tolerance. We found that both imDCs and CD45RB<sup>+</sup> DCs inhibited proliferation of T cells, prompting differentiation towards Th2, and increasing the proportion of CD4+Foxp3+ T cells. However DC45RB<sup>+</sup> DCs were not identical to imDCs. T cells incubated with CD45RB<sup>+</sup> DCs secreted more IL-10 than those incubated with imDCs or mDCs. This observation suggests that the mechanism by which CD45RB<sup>+</sup> DCs influence T cell responses differs, at least in part, from the effect of imDCs. The immunosuppressive effect of IL-10 has been previously reported [16, 19, 30], thus we conclude that MSCs may exert immunosuppressive effects by inducing CD45RB<sup>+</sup> DCs differentiation.

The mechanism by which of CD45RB<sup>+</sup> DCs differentiate is not well understood. Delgado *et al.* previously reported the vasoactive intestinal peptide (VIP) and the pituitary adenylate cyclase-activating polypeptide (PACAP) induced CD45RB<sup>+</sup> DCs by stimulating theVPAC1 receptor and protein kinase A [31]. In future studies, the pathway by which MSCs induce CD45RB<sup>+</sup> DC maturation will be further investigated.

Taken together, we conclude that co-incubation of MSCs and DCs inhibited maturation of im-DCs into mDCs and induced differentiation of CD45RB<sup>+</sup> DCs. CD45RB<sup>+</sup> DCs further inhibited proliferation of CD4<sup>+</sup> T cells, and induced differentiation of CD4<sup>+</sup> T cells to Th2 and Tregs.

#### Acknowledgements

This study was supported by National Natural Science Foundation of China (No. 81401316).

#### Disclosure of conflict of interest

None.

Address correspondence to: Zhenya Shen, Department of Cardiovascular Surgery, Institute of Cardiovascular Science, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215-006, Jiangsu, China. Tel: +86-13606210812; Fax: +86-21-57643271; E-mail: uuzyshen@sina.com

#### References

 Zhao K and Liu Q. The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. J Hematol Oncol 2016; 9: 46.

- [2] Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M and Lagneaux L. Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. Cytotherapy 2016; 18: 160-171.
- [3] Mamidi MK, Das AK, Zakaria Z and Bhonde R. Mesenchymal stromal cells for cartilage repair in osteoarthritis. Osteoarthritis Cartilage 2016; 24: 1307-1316.
- [4] Malhotra S, Hu MS, Marshall CD, Leavitt T, Cheung AT, Gonzalez JG, Kaur H, Lorenz HP and Longaker MT. Mesenchymal stromal cells as cell-based therapeutics for wound healing. Stem Cells Int 2016; 2016: 4157934.
- [5] Ezquer F, Bruna F, Calligaris S, Conget P and Ezquer M. Multipotent mesenchymal stromal cells: a promising strategy to manage alcoholic liver disease. World J Gastroenterol 2016; 22: 24-36.
- [6] Thanunchai M, Hongeng S and Thitithanyanont A. Mesenchymal stromal cells and viral infection. Stem Cells Int 2015; 2015: 860950.
- [7] Castro-Manrreza ME and Montesinos JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res 2015; 2015: 394917.
- [8] Uccelli A and de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann N Y Acad Sci 2015; 1351: 114-126.
- [9] Liu YJ, Kanzler H, Soumelis V and Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001; 2: 585-589.
- [10] Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD and Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126.
- [11] Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, Daudt L, Ibatici A, Piaggio G, Pozzi S, Frassoni F and Locatelli F. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ Tcell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516-525.
- [12] Spaggiari GM, Abdelrazik H, Becchetti F and Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009; 113: 6576-6583.
- [13] Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R and Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177: 2080-2087.
- [14] Sadeghi L, Kamali-Sarvestani E, Azarpira N, Shariati M and Karimi MH. Immunomodulatory

effects of mice mesenchymal stem cells on maturation and activation of dendritic cells. Iran J Immunol 2014; 11: 177-188.

- [15] Banchereau J and Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
- [16] Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F and Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003; 18: 605-617.
- [17] Fujita S, Seino K, Sato K, Sato Y, Eizumi K, Yamashita N, Taniguchi M and Sato K. Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response. Blood 2006; 107: 3656-3664.
- [18] Liu QY, Yao YM, Zhang SW, Yan YH and Wu X. Naturally existing CD11c(low)CD45RB(high) dendritic cells protect mice from acute severe inflammatory response induced by thermal injury. Immunobiology 2011; 216: 47-53.
- [19] Svensson M, Maroof A, Ato M and Kaye PM. Stromal cells direct local differentiation of regulatory dendritic cells. Immunity 2004; 21: 805-816.
- [20] He J, Teng X, Yu Y, Huang H, Ye W, Ding Y and Shen Z. Injection of Sca-1+/CD45+/CD31+ mouse bone mesenchymal stromal-like cells improves cardiac function in a mouse myocardial infarct model. Differentiation 2013; 86: 57-64.
- [21] Huang H, He J, Teng X, Yu Y, Ye W, Hu Y and Shen Z. Combined intrathymic and intravenous injection of mesenchymal stem cells can prolong the survival of rat cardiac allograft associated with decrease in miR-155 expression. J Surg Res 2013; 185: 896-903.
- [22] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D and Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006; 8: 315-317.
- [23] Cahill EF, Tobin LM, Carty F, Mahon BP and English K. Jagged-1 is required for the expansion of CD4+ CD25+ FoxP3+ regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells. Stem Cell Res Ther 2015; 6: 19.

- [24] Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z and Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: 7018-7031.
- [25] Fontenot JD, Gavin MA and Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
- [26] Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, Miyachi Y, Tsukada T and Sakaguchi S. Foxp3 controls regulatory Tcell function by interacting with AML1/Runx1. Nature 2007; 446: 685-689.
- [27] Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G and Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83: 71-76.
- [28] Aggarwal S and Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
- [29] Kronsteiner B, Peterbauer-Scherb A, Grillari-Voglauer R, Redl H, Gabriel C, van Griensven M and Wolbank S. Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. Cell Immunol 2011; 267: 30-38.
- [30] Liu QY, Yao YM, Zhang SW and Sheng ZY. Astragalus polysaccharides regulate T cell-mediated immunity via CD11c(high)CD45RB(low) DCs in vitro. J Ethnopharmacol 2011; 136: 457-464.
- [31] Delgado M, Gonzalez-Rey E and Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 2005; 175: 7311-7324.